Legal Representation
Attorney
Bryce J. Maynard
USPTO Deadlines
Next Deadline
2095 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2025-04-08)
Due Date
April 08, 2031
Grace Period Ends
October 08, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
23 events| Date | Code | Type | Description |
|---|---|---|---|
| Apr 8, 2025 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Apr 8, 2025 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Feb 18, 2025 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Feb 18, 2025 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Feb 12, 2025 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Jan 27, 2025 | ALIE | A | ASSIGNED TO LIE |
| Jan 27, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Jan 27, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Jan 27, 2025 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Jan 15, 2025 | ERSI | I | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED |
| Oct 7, 2024 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Oct 7, 2024 | GNSL | F | LETTER OF SUSPENSION E-MAILED |
| Oct 7, 2024 | CNSL | R | SUSPENSION LETTER WRITTEN |
| Oct 2, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Oct 2, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Oct 2, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Sep 11, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED |
| Sep 11, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Sep 11, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Aug 29, 2024 | DOCK | D | ASSIGNED TO EXAMINER |
| Mar 15, 2024 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Mar 14, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Feb 9, 2024 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 005
Pharmaceutical preparations for the prevention and treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, infection and immune system related diseases; synthetic peptides for pharmaceutical use for the prevention and treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, infection and immune system related diseases; vaccines
Additional Information
Design Mark
The mark consists of the stylized wording "CYLEMBIO" in blue with a circle made up of ten circles of varying sizes in varying shades of blue and purple in a circular pattern above the letter "I".
Color Claim
The color(s) blue and purple is/are claimed as a feature of the mark.
Classification
International Classes
005
USPTO Documents
Loading USPTO documents...